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Organ-on-a-chip (OoC) is an emerging technology which combines microfluidics with cell culture 
to create platforms that replicate human organs. These predictive models are used to understand 
human physiology and to predict responses to medical treatments. Being the small intestine the 
largest interface between the environment and the human organism and one of the most important 
organs involved in drug metabolism, there is an increasing interest from researchers and the 
pharmaceutical industry for reliable in vitro intestine models. However, currently available gut-on-
a-chip devices that replicate the complex microenvironment found in the in vivo tissue are scarce, 
limiting their translational capabilities to clinical outcomes. Therefore, in this work we aim to develop 
a reproducible gut-on-a-chip device that mimics the 3D architecture and cell heterogeneity of the 
small intestinal mucosa. SLA 3D bioprinting will be used to fabricate cell-encapsulating GelMA-
PEGDA hydrogels that support the formation of an epithelial monolayer on top, to replicate the two 
compartments of the intestinal mucosa; the lamina propria and the intestinal epithelial barrier. The 
hydrogels contain fibroblasts and immune cells, which play a key role in maintaining the intestinal 
mucosa integrity and homeostasis. These scaffolds will be then incorporated into PDMS 
microfluidic chips to create the final biomimetic system. Although further improvements are needed, 
this gut-on-a-chip, obtained using precise and fast fabrication techniques, might be a useful tool for 
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Organ-on-a-chip (OoC) microdevices aim to create in vitro models of human organs by simulating 
the in vivo environment found in the tissues, combining microfluidics with cell culture [1]. These 
predictive models are used to understand the human body functions and the pathogenic 
mechanisms of disease for drug development and toxicity assessment.  
The need for biomimetic systems arises from the major gap between the current in vivo and in vitro 
models. In the preclinical phase of drug development, compounds are tested in 2D cell cultures. 
Although these cultures give primary information on the effect of the substances in cell activity, they 
are inadequate to predict patient outcomes, as they do not mimic the complex dynamic tissue 
microenvironment [2]. Therefore, the pharmaceutical industry is interested in the development of 
platforms that allow for rapid, efficient, cost-saving and reliable drug screening, reducing the need 
for animal testing [3].  
One of the most important organs when studying pharmacokinetics is the gut. Drugs administered 
through the oral route have to be absorbed in the small intestine in order to enter the bloodstream 
and be distributed throughout the body. This tissue is formed by several layers, being the intestinal 
mucosa the innermost layer and in direct contact with the external environment. It is responsible 
for protection against pathogens, nutrient absorption, and waste secretion, and is made up of an 
epithelial barrier and an underlying lamina propria, followed by muscular layers [4]. To increase the 
surface area where nutrients absorb, the tissue presents a characteristic architecture of 
protrusions, called villi, followed by invaginations, known as crypts [5] (Figure 1). The epithelial 
monolayer is composed of different cell lineages (enterocytes, enteroendocrines, Paneth cells, Tuft 
cells, Goblet cells and stem cells) which are characteristically distributed throughout the crypt-villus 
domains. The most abundant cells are the enterocytes, which are highly polarized absorptive cells 
that present microvilli on the apical side exposed to shear stress. Differently, the lamina propria is 
connective tissue with residing fibroblasts, myofibroblasts and immune cells that support the 





Figure 1. Schematic of the intestinal mucosa with the crypt-villus architecture. The epithelial monolayer is composed of enterocytes, 
enteroendocrines, Paneth cells, Tuft cells, Goblet cells and stem cells. The underlying lamina propria has residing fibroblasts, 
myofibroblasts and immune cells that support the intestinal barrier function. (Created in BioRender.com). 
Given the complexity of the living tissue, it is challenging to mimic the small intestinal mucosa. 
Specifically, OoC models that incorporate the structural features and recreate the cell heterogeneity 
of the gut are scarce. Therefore, this project is focused on fabricating a gut-on-a-chip device, which 
simulates, on the one hand, the stromal compartment by incorporating a 3D cell-encapsulating 
hydrogel with crypt-villus architecture and, on the other hand, the intestinal barrier, by growing an 
epithelial monolayer on top. To create a reproducible and cost-effective system, digital light 
projection stereolithography (DLP-SLA) 3D bioprinting will be used to fabricate the hydrogels with 
embedded fibroblasts and immune cells. All of this will be carried out in combination with 
microfluidic technology to obtain the final gut-on-a-chip device.  
 
1.1. Objectives 
The project seeks to fabricate a reproducible gut-on-a-chip device that mimics the small intestinal 
mucosa. To do so, 3D SLA bioprinting and microfluidic technology will be used in combination with 
cellular cultures.  To meet the primary goal, some secondary objectives are defined:  
- To fabricate hydrogel scaffolds using SLA 3D bioprinting.  
- To determine the hydrogel scaffold pore size. 
- To encapsulate intestinal stromal cells (fibroblasts and immune cells) into the bioprinted 
hydrogels and assess their behavior in a 3D microenvironment.  
- To obtain a model of the intestinal mucosa with epithelial and stromal cells and monitor the 
barrier properties.   
- To obtain a gut-on-a-chip device containing the cell-laden hydrogel and the microfluidic 







1.2. Project scope  
The project was carried out between the 1st of February and the 22nd of June of 2021 in the 
Biomimetic Systems for Cell Engineering research group at the Institute for Bioengineering of 
Catalonia (IBEC). It was divided into different stages, which are explained in detail in Section 6.  In 
short, first, a literature review was carried out, followed by an experimental part, and finishing with 
a result analysis.  
 
For the experimental research, a previous training, completed during the summer months of 2020, 
was necessary in order to use all the IBEC’s facilities and to learn the basic laboratory techniques. 
The experimental research consisted of the fabrication and characterization of the bioprinted 
hydrogels, first without cells embedded for pore size determination and then with stromal cells 
encapsulated. Monocytes and fibroblasts containing hydrogels were fabricated and epithelial cells 
were seeded on top, mimicking the lamina propria and the epithelial barrier. The co-cultured 
hydrogels were studied alongside hydrogels laden with immune cells alone, to evaluate their 
differentiation into macrophages. As it is difficult to incorporate sensors into the microfluidic device, 
cell behavior inside hydrogels was first studied in static Transwell® models. After verification of 
epithelial barrier formation and monocyte differentiation in flat hydrogels, the gut-on-a-chip was 
assembled. This included the microfluidic chip with the cell-laden hydrogel presenting a villus-crypt-
like architecture. Owing to the time restrictions, we were not able to develop a fully functional 
system, thus, further experiments are needed.  
 
1.3. Memory structure 
The result analysis was followed by the report preparation and writing. The memory includes a brief 
introduction containing the motivation and goals of the project. Following, the state of the art of 
OoC technology and the commercialized products are reviewed. Next, the methodology of the 
experiments carried out is described and the obtained results are discussed. The report also 
includes the technical and economic feasibility and viability of the project, as well as the current 
regulations regarding OoC. Finally, the conclusion and future improvements are stated. 
  
2. Background 
2.1. From microfluidics to organ-on-a-chip 
OoC based devices appeared over a decade ago as an evolution of Lab-on-a-Chip (LoC), which 
emerged after the appearance of microfluidic technologies. Microfluidics is the use of 
microminiaturized devices with different compartments, such as channels, pumps, mixers or 
separators that support the study of the fluid’s behavior. Reducing the scale induces a laminar flow 
enabling more precise control of the system, all with less sample volume [7]. Therefore, 
microfluidics has reinforced the development of LoC devices, which integrate multiple laboratory 





The OoCs devices can be classified into three different groups: OoCs that emulate the barrier 
function of a tissue, OoCs that replicate one specific organ, and microfluidic platforms that 
incorporate multiple interconnected organs to study their interaction [9].  
 
Generally, all OoC devices include two main components, microfluidics and 2D or 3D living cell 
tissues. The first component comprises the channels that will reproduce the fluid flow in the human 
body, distributing the nutrients and oxygen throughout the tissue model. Furthermore, the 
microchannels are used to induce specific states for studying pathological processes or to deliver 
drugs. For fabrication of the microfluidic chip [10], [11]poly(methyl methacrylate) (PMMA)[12], [13] 
and polydimethylsiloxane (PDMS) are widely used materials  [10], [11],[12], [13]. However, PDMS 
has become the most popular as it presents unique characteristics including gas permeability, 
biocompatibility, cytocompatibility elasticity, low cost and optical transparency.  
 
As for fabrication techniques, soft lithography has become the foundation of OoCs fabrication due 
to its simplicity and low cost. It consists of curing soft elastomers on a master mold with the desired 
micropatterns. Yet, 3D printing is gaining attention since it allows for automated and high-resolution 
fabrication while giving the possibility for the direct incorporation of the tissue component into the 
microfluidic device [14]. 
 
The second component in OoC is the cell culture, or biological component, and is simulated with a 
combination of cells and proteins. Advancements are made on the incorporation of 3D scaffolds 
that simulate the structural features of the tissue.  In this context, hydrogels have drawn most of 
the attention as these polymeric networks absorb high amounts of water mimicking the extracellular 
matrix (ECM). Furthermore, their mechanical and chemical properties can be tuned by changing 
the composition, polymerization method and crosslinking density. For hydrogel fabrication, 
synthetic (e.g. polyvinyl alcohol, polyethylene glycol, polyacrylic acid, etc.)  or natural polymers 
(e.g. collagen, gelatin, chitosan, alginate, pectin, etc.)  can be used [15]. The natural polymers are 
biocompatible and biodegradable but lack mechanical stability. The synthetic ones provide 
structural integrity and prevent fast degradation, but they lack cell adhesion motifs. Thus, a 
combination of the two would give the best results for cell-laden hydrogels with topographical 
features.  
 
One of the main fabrication techniques of hydrogel scaffolds is bioprinting due to its high resolution, 
versatility, and throughput. 3D bioprinting can be classified in extrusion-based, inkjet-based, laser-
assisted, or stereolithography (SLA) [16]. Among them, SLA presents the best attributes for 
fabricating cell-encapsulating hydrogels due to its low cost, lack of pressure exertion, and high 
speed, reducing time exposure of cells to non-physiological conditions [14]. It is based on the 




prepolymer solution with cells, inducing the photocrosslinking of the biomaterial in a layer-by-layer 
manner (Figure 2).  
 
 
Figure 2. Schematic of working principle of SLA bioprinting technique. A building platform is submerged into the photocrosslinkable 
prepolymer and light is irradiated triggering the curing of a layer in its surface. Once polymerized the platform moves upwards in the 
z-direction, after which light is irradiated again with a new pattern, adding a newly cured layer on top of the previous one. (Created 
in BioRender.com) 
2.2. Gut-on-a-chip 
Efforts in the gut-on-a-chip field are focused on emulating the absorption and metabolism function 
of the intestine, incorporating physiological realistic cell types, a 3D villus-crypt architecture, fluid 
flow and peristaltic motion [17].    
 
The simplest intestine chip models are microfluidic systems with two channels, separated by a 
porous membrane with immortalized intestinal epithelial cells seeded on top replicating the 
intestinal barrier [18].  One channel represents the gut lumen whereas the other channel the blood 
stream, and are both perfused with a continuous laminar flow of culture medium (Figure 3 (a)). 
These models are mainly used for permeability assays.  
 
The complexity of these systems is increased with the addition of biochemical and biomechanical 
cues, similar to the one's tissues experience under physiological conditions [9]. The biomechanical 
cues play a key role in tissue maturation and different gut-on-chip models have been developed to 
incorporate this increased complexity. On the one hand, it has been proved that the stiffness and 
topography of the scaffolds can regulate the cell activity and its resemblance to the native human 
gut  [19]. Therefore, villus-shaped structures have been incorporated into the microfluidic device. 
For example, Shim et al. developed a microfluidic gut model that incorporated a 3D villi collagen 
scaffold fabricated with photolithographic technique (Figure 3 (b)) [20]. On the other hand, 
mechanical active stimuli such as tensile stretching have been proved to induce epithelial cell 
polarization and differentiation. Kim et al. generated a model with cyclic peristalsis-like mechanical 
deformations by incorporating two lateral channels subjected to suction cycles (Figure 3 (c)) [10].  




static conditions remained flat. Commensal microbes were also integrated into the model, to study 
their interaction with epithelial cells and their contribution to intestinal homeostasis.  
 
One of the most recent works in this field has been carried out by Lutolf et al. [11].  They have 
developed a hydrogel-based microfluidic chip with a crypt-like architecture that induces organoid 
morphogenesis (Figure 3 (d)). The 3D topography, obtained with the laser-ablation technique, 
triggered the differentiation of intestinal stem cells into the distinct cell types found in the intestinal 
epithelium that were spontaneously arranged across the crypt and villus domains as in the in vivo 
tissue. Moreover, they included stromal cells, such as myofibroblasts and immune cells that 
supported the tissue barrier function.  
 
 
Figure 3. Intestine-on-a-chip devices. (a) Schematic of a simple microfluidic intestinal barrier model, composed of two channels 
separated by an epithelial monolayer. Adapted from Ref. 18 [18](b) Schematic of the assembly of a microfluidic intestinal model with 
a 3D villus-like collagen scaffold. Adapted from Ref. 20. (c) Schematic of intestine-on-a-chip that recreates the in-vivo mechanical 
forces.  (i) Cross-section of the device with lateral vacuum chambers. (ii) Schematic vacuum chambers suction to generate a cyclic 
stretch of the membrane. Adapted from Ref 10.  (d) Mini-intestine 3D hydrogel-containing microdevice (i) Schematic of the 
microfluidic device. (ii) Photograph of the top view of the channel with the 3D crypt-shaped hydrogel of collagen/Matrigel and 
dimensions. Adapted from Ref 11.  
The present study is a continuation of the previous work from the group [21], in which they 
developed a model of the intestinal mucosa using gelatine methacrylate (GelMA) – poly(ethylene 
glycol) diacrylate (PEGDA) hydrogel co-networks. This scaffold allowed for the encapsulation of 
intestinal fibroblasts with high adhesion and viability, as well as the intestinal epithelial monolayer 
formation on top. A follow-up study encapsulated immune cells together with fibroblasts inside the 
GelMA-PEGDA hydrogels [22] and demonstrated that this immune component had an important 
role in the intestinal barrier properties. However, these hydrogels were not incorporated into 
microfluidic chips and presented no topographical features.  
 
Therefore, we will use the projector-based SLA 3D bioprinting technique to rapidly fabricate well-




incorporate an immune component into the stromal compartment to replicate the immune-
modulatory functions of the intestine while integrating the hydrogels into a PDMS microfluidic chip.  
The final complete intestine model is shown in Figure 4.   
 
Figure 4. Bioprinted gut-on-a-chip to mimic the small intestinal mucosa. The model is composed of a microfluidic chip with two 
channels, recreating the lumen and blood-stream, that incorporates a cell-laden hydrogel with crypt-villus architecture and with 
epithelial cells seeded on top. Created in BioRender.com.  
This chip provides several advantages in comparison with already existing models. Firstly, it does 
not only replicate the epithelial barrier but also the lamina propria and its immune system function. 
Thus, increasing the complexity and functionality of the model. Secondly, the microfluidic device 
incorporates an ECM-like matrix with a 3D architecture that resembles the native tissue, combining 
natural and synthetic polymers. Third, it uses a projector-based SLA bioprinting technique for the 
fabrication of the constructs. This method allows for high-resolution, mechanically robust and fast 
cell-laden hydrogel fabrication, that ensures cell viability up to 95% [16], [23]. Lastly, a customized 
commercially available 3D printer is used, reducing the costs that come from highly specialized 
bioprinter. Additionally, this printer gives us the possibility of printing several hydrogels 
simultaneously by increasing the moving platform surface.  
 
3. Market analysis 
The OoC concept appeared in 2010 when the first successful lung-on-a-chip device was produced 
by the Wyss Institute led by Donald Ingber [24]. The same group later founded Emulate, one of the 
first commercial OoC ventures. They now offer supported models of liver, kidney, and intestine, as 
well as microfluidic chips that can be configured to emulate many organs. New companies have 
emerged since, offering different alternatives of single chips; Alveolix, TARA Biosystems, Synvivo 
or Nortis, to name a few.  
 
TissUse and Hesperos are bringing body-on-a-chip devices to the market with, for instance, the 
HUMIMC and Heart-liver-skeletal muscle-neuron four organ model, respectively. These models 





Another pioneer in the field is MIMETAS, who introduced hydrogel-liquid interfaces into their 
microfluidic chips to mimic the ECM. Furthermore, they also lead the advancements onto creating 
multi-chip plates for throughput screening (OrganoPlate 2-lane 96). This approach has also been 
followed by AimBiotech. 
 
Regarding intestine models, Emulate commercializes the Emulate Colon Intestine-Chip that 
combines organoid-derived epithelium with colon-specific endothelium and mechanical forces. 
There are no other gut-on-a-chip devices, although we find publications in which research groups 
use the customizable commercialized models to seed intestinal cells [25].   
 
In 2020 the microfluidic market size was valued at USD 17.9 billion, in which the organ on a chip 
presence is increasing and is expected to expand at a compound annual growth rate (CAGR) of 
21.9%, as it will be adopted by new markets, including hospitals and cosmetic and chemical 
industries [26].   
Given the complexity of the gut, it is challenging to create robust biomimetic microsystems that can 
be put on the market and so the focus is on integrating the morphological characteristics and 
dynamic environment while extending the device life span [27]. Furthermore, for improved 
functional readout, the incorporation of built-in sensors is being studied. Provided that the main 
end-users are pharmaceutical companies, life science companies, research institutes and contract 
research organizations, who are looking for efficient and cost-saving techniques for in vitro testing, 
the industry is questing to find a balance between complexity and costs. The final goal is to create 
reproducible, simple, and cost-effective systems for commercial use. Therefore, this project aims 
at creating a gut-on-a-chip that satisfies the current demands of the market using 3D bioprinting.  
The use of 3D bioprinting technology to fabricate hydrogel scaffolds that can be integrated in the 
microfluidic chip has not been adopted yet by the developers. The bioprinting concept appeared in 
the early 2000s when its potential for tissue engineering, therapeutic or drug screening applications 
was discovered. Organovo is considered the first 3D bioprinting company, specialized in fabricating 
tissue models with inkjet-based modality, and was followed by RegenHu and Poietis in the 
commercialization of extrusion-based and light-based 3D bioprinters, respectively.  However, 
owing to the high costs, research groups opted for the adaption of commercially available 3D 
printers to create tissue constructs.  Consequently, Allevi, CELLINK and Se3D emerged with 
affordable general bioprinters [28]. The market was valued in 2020 at USD 1.4 billion and is 





4. Concept engineering  
4.1. Cell culture 
The intestine has a complex microenvironment, formed by different cell types that support its 
function. Enterocytes, which are hyperpolarized epithelial cells, are the most important constituents 
of the intestinal barrier.  Although this epithelial barrier plays a key role in protection against 
pathogens and nutrient absorption, many other cell types found in the underlying lamina propria 
are crucial for supporting this barrier function while maintaining homeostasis [4]. To name a few, 
macrophages, lymphocytes, fibroblast, and myofibroblasts.  For the fabrication of a 3D model of 
the gut, three different cell cultures were used: NIH-3T3 as fibroblasts, THP-1 as monocytes that 
are differentiated into macrophages, and Caco-2 BBe as enterocytes. 
4.1.1. NIH-3T3 fibroblasts 
The NIH-3T3 (ATCC® CRL-1658™) is a mouse embryonic fibroblast cell line. The cells are cultured 
in flasks with Dulbecco’s Modified Eagle’s Medium (DMEM Medium) (Gibco) supplemented with 
10% (v/v) of Fetal Bovine Serum (FBS) (Gibco) and 1% of (v/v) Penicillin/Streptomycin (Pen/Strep) 
(Sigma-Aldrich). We will refer to this medium as Supplemented DMEM. They are incubated at 37ºC 
and 5% CO2. Cells were subcultured when reaching 80-90% confluency. To do so, the culture 
medium from the flask was discarded, and cells were washed with phosphate-buffered saline 
solution (PBS) (Thermo Fisher) to eliminate all the remains of serum containing trypsin inhibitors. 
Afterwards, cells were incubated with Trypsin-EDTA (Thermo Fisher) solution for 5 min, or until 
they were detached from the surface. Supplemented DMEM was added to inhibit trypsin enzymatic 
activity and cells were centrifuged at 1200 rpm for 5 min. The pellet was then resuspended and 
seeded in a new flask at a ratio of 1:10.  
 
4.1.2. Brush border expressing human epithelial colorectal adenocarcinoma (Caco-
2 BBe) 
The Caco-2 BBe cells (ATCC® CRL-2102™) are cloned from the human colorectal 
adenocarcinoma derived cell line, Caco-2. The cells form a polarized monolayer with an apical 
brush border (BB). They are cultured in flasks with Supplemented DMEM at 37ºC and 5% CO2. 
Cells were subcultured when reaching 80-90% confluency. As explained above, cells were washed 
with PBS and trypsinized. After blocking the trypsin activity with Supplemented DMEM, cells were 
centrifuged at 900 rpm for 5 min. The pellet was then resuspended, and the 250.000 cells were 
seeded in a new T75 flask.  
 
4.1.3. THP-1 monocytes 
The THP-1 (ATCC® TIB-202™) is a human leukemia monocytic cell line. The cells are cultured 
with Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco) supplemented with 10% (v/v) 




piperazineethanesulfonic acid (HEPES) (Gibco) and 0.1% (v/v)  β-mercaptoethanol (Gibco), which 
was added just before use. We will refer to this medium as Supplemented RPMI. They are cultured 
in suspension at a density of 2x105 cells/mL in non-adherent T75 culture flasks and incubated at  
37ºC and 5% CO2. When cell concentration arrived at a maximum of 1x106 cells/mL they were 
subcultured by dilution with Supplemented RPMI to reach a concentration of 2x105 cells/mL.  
 
In some experiments, THP-1 cells were differentiated into macrophages-like cells (M0). To induce 
the differentiation, 8x106 cells were seeded in a petri dish with Supplemented RPMI with phorbol 
12-myristate 13-acetate (PMA) at 50 ng/mL. After 72 h, the medium containing PMA was discarded, 
cells were rinsed with PBS and incubated with 3mL Accutase® cell detachment solution for 10 min 
in the incubator. With the help of a cell scraper, cells were carefully detached from the surface and 
7 mL of Supplemented RPMI Medium was added to inactivate the Accutase® enzymatic activity. 
Lastly, the suspension of differentiated THP-1 was centrifuged at 400xg for 5 min with a slow 
deacceleration.  
4.2. Synthesis of gelatin methacryloyl (GelMA) 
Gelatin methacryloyl (GelMA) is synthesized by the reaction of gelatine with methacrylic anhydride 
(MA) following the method described previously [30]. The methacryloyl groups of MA react and 
bond to the amino groups present in the side chains of gelatin, forming modified gelatin that can 
be photocrosslinked.  
 
Gelatin from porcine skin type A (Sigma-Aldrich) was dissolved in sterile PBS at a concentration of 
10% (w/v) at 50ºC for 1 h. Then, the MA (Sigma-Aldrich) was added to the gelatin solution at 0.5 
mL/min using a syringe pump (NE-1000 Programmable Single Syringe Pump, New Era) to get a 
final concentration of 1.25% (v/v) MA. After complete addition, the reaction was kept under stirring 
conditions at 50ºC for 1 h. The solution was then centrifuged at 1200 rpm for 3 min at 20ºC to 
remove the unreacted MA. The supernatant was diluted in warm PBS (40ºC) to double its volume 
to stop the reaction. Finally, the solution was dialyzed against MiliQ water bath at 40ºC using 
dialysis membranes (Spectra/Por® 1 Dialysis Membranes, MWCO 6000 to 8000, Spectrum ®), 
previously hydrated. This step is required to eliminate all the byproducts and unreacted MA. The 
membranes were left for 3 days in MiliQ water, which was changed three times a day. Finally, the 
pH of the GelMA solution was adjusted at 7.4, distributed in 50 mL falcon tubes and lyophilized for 
3-4 days to obtain a foamy solid. The final product is then kept in the freezer at -20ºC until use.  
 
4.2.1. Determination of the degree of functionalization of GelMA 
The degree of methacrylation of the GelMA used in the bioink will affect the fabrication conditions 
and the properties of the hydrogel [30]. This property is quantified by the TNBSA assay, a method 
developed by Habeeb 1966 [31]. When MA reacts with gelatin, it bonds to reactive amine groups 




reacts with the still available amino groups in an aqueous solution at pH 8 and produces an orange-
colored derivative, whose absorbance at 335 nm can be measured.  Therefore, by measuring the 
absorbance, the number of free amino groups can be quantified, and thus the methacrylation.   
 
To perform this assay gelatin and GelMA (known and unknown concentration) were dissolved in 
carbonate buffer (0.1 M NaHCO3, pH 8.4) (Sigma-Aldrich) at a concentration of 2 mg/mL. To 
generate a standard curve, a serial dilution of 100 L of gelatin and GelMA solutions were placed 
in a 96-well plate (Thermo Scientific™). Wells with only carbonate buffer were also added as blank. 
Then, 50 μL of working solution (TNSBA 0.01% in carbonate buffer) (Sigma-Aldrich) was added 
and the plate was incubated at 37ºC for 2 h in the dark. Next, the reaction was stopped and 
stabilized by adding 50 μL of sodium dodecyl sulfate (SDS) (Sigma-Aldrich) at 10 % (w/v) and 25 
μL of HCl 1 M in Milli-Q water to each well. Absorbance was measured at a wavelength of 335 nm 
with a microplate reader (Infinite M200 PRO Multimode Microplate Reader, Tecan). The resulting 
values were used for calculating the degree of methacrylation of GelMA, comparing the calibration 
curve of the gelatin solution (total of free amines available) to the calibration curve of the GelMA 
solution. 
 
Finally, the percentage of methacrylated lysines, also known as the degree of methacrylation, was 
calculated with Equation 1.  
𝐷𝑒𝑔𝑟𝑒𝑒 𝑀𝑒𝑡ℎ𝑎𝑐𝑟𝑦𝑙𝑎𝑡𝑖𝑜𝑛 = 100 − % 𝑓𝑟𝑒𝑒 𝑎𝑚𝑖𝑛𝑒𝑠 Eq. 1 
  
4.3. Hydrogel fabrication  
4.3.1. Bioink preparation 
The fabricated hydrogels should have robust mechanical properties that allow for the printing of the 
hydrogel channel with villus-like microstructures as well as cell adhesion motifs that allow for cell 
encapsulation, proliferation, and migration. For this reason, the polymer solution (bioink G8) is 
composed of 5% (w/v) GelMA, suitable for cell adhesion and biodegradable, 3% (w/v) poly(ethylene 
glycol) diacrylate (PEGDA) (Sigma-Aldrich), synthetic polymer that provides mechanical stability, 
(0.4% w/v) lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) (TCI Chemicals) as 
photoinitiator and (0.025% w/v) tartrazine (Sigma-Aldrich) as photo absorber. This last component 
is a synthetic dye that acts as a photo blocker by absorbing light at 405 nm and is crucial for 
enabling high print resolution. 
 
To prepare the G8 bioink, PEGDA, LAP and tartrazine were dissolved in Hank’s Balanced Salt 
Solution (HBSS) (Gibco) supplemented with 1% (v/v) Pen/Strep at 65ºC for 1 h and then filtered 
using a 0.22 μm filter. In parallel, GelMA was dissolved in supplemented HBSS at 65ºC. Once 




bioink. For cell encapsulation, NIH-3T3 and/or THP-1 were trypsinized as explained above and 
counted to have a concentration of 6.5x106 cells/mL each. The desired volume of cell suspension 
was extracted and centrifuged. After centrifugation, the supernatant is carefully removed and 
directly resuspended in the polymer solution, to obtain the cell-containing G8 bioink. 
 
4.3.2. Substrate silanization 
The silanization with vinyl groups of the substrate on which the hydrogel is fabricated, round 
coverglass (VWR, 13 mm diameter) or polyethylene terephthalate (PET) membranes (it4ip, 10 mm 
diameter, 0.4 μm pore size), improves its attachment upon printing.  In this process, the surface of 
the substrate is activated with a UV ozone cleaner (ProCleaner™, Bioforce Nanosciences) for 15 
min. Directly after, the substrates were incubated in a solution containing 2% (v/v) 3-
(trimethoxysilyl)propyl methacrylate (Sigma-Aldrich), 3% (v/v) acetic acid (diluted 1:10) and 95 % 
(v/v) absolute ethanol for 2 h and then rinsed thoroughly with ethanol. Then, the substrates were 
placed in the oven at 65ºC for 30 min.  Silanized substrates were stored in the vacuum desiccator 
until use.  
 
4.3.3. 3D bioprinting of the hydrogel 
The hydrogels were fabricated using SLA bioprinting. The printing setup was a customization of 
the commercially available Solus 3D printer (Junction3d), a DLP (digital light processing) projector-
based SLA printer (Figure 5). The printing setup consists of a vat, adapted to the small dimensions 
of the hydrogels, pre-heated at 37ºC where the bioink is introduced. The light is projected through 
an HD beam projector coupled to an infrared cut-off filter to restrict the light projection to the visible 
range. Additionally, the printer has a building platform attached to a z-axis actuator where the 
substrate (silanized PET or coverglass) is attached and the hydrogel will be printed.  
 
Figure 5. (a) Commercially available Solus 3D printer (Junction3d). (b) Customized Solus 3d printer set up, with miniaturized tank 
and build platform for hydrogel printing.  
The printing process entails different steps. First, a 3D CAD design with the desired structure is 
created with the modeling software program FreeCAD. Two different designs were employed for 




were printed for the preliminary static measurements in Transwell® inserts (Figure 6 (a)). This 
simple design is used for studying the behavior of cells when being embedded in polymeric 
scaffolds. On the other hand, rectangular hydrogels (7x4x0.5mm) with micropillars that resemble 
the 3D villi intestinal architecture were fabricated for gut-on-a-chip experiments (Figure 6 (b)).  
 
Figure 6. Hydrogel FreeCAD designs. (a) Disc design for static measurements in Transwell® inserts. (b) Rectangular channel-like 
design with micropillars.  
The design is uploaded to the printer software and the proper printing parameters, regarding build 
resolution and layer printing parameters, are chosen. Then the printing process goes as follows: 
the liquid polymer solution is introduced into the tank. The building platform is submerged in the 
mixture and its surface is then irradiated with a light pattern, triggering the photopolymerization of 
a thin layer. Once the solution has polymerized the building platform moves upwards in the z-
direction and light is irradiated again with a new pattern, adding a newly cured layer on top of the 
previous one. This process continues layer-by-layer until obtaining a 3D structure with the desired 
morphology.   After printing the hydrogels were rinsed with warm PBS and removed from the 
platform.  
 
Moreover, the printing parameters used for fabricating the hydrogels were optimized to have the 
appropriate mechanical properties, whilst ensuring cell viability. The optimized values are 
hereunder detailed:  
- Layer thickness: 13m 
- Layer exposure time: 5s 
- Initial layer exposure time: 15s 
- Number of initial layers: 2 
- Exposure buffer time: 1s 
 
4.3.4. Transwell assembly  
For cell experiments, hydrogels fabricated onto PET membrane substrates were mounted on 
modified Transwell® inserts as described in [21], [32] (Figure 7). Briefly, the standard polycarbonate 
membrane was removed from the inserts. Then, a first ring of pressure-sensitive adhesive (PSA) 




The hydrogel-containing membrane was then adhered to the PSA ring.  Finally, a second PSA ring 
was attached to the bottom of the PET to prevent leakage. Afterwards, 200 L of PBS (or 
Supplemented DMEM when encapsulating cells) were added to the upper compartment and 600 
L to the lower compartment. 
 
 
Figure 7. Schematic of the Transwell® assembly process. Created with BioRender.com. 
4.4. Characterization of hydrogel network  
The structural characterization of the hydrogels is of great interest as it affects cell behavior [33]. 
Besides, our hydrogels encapsulate intestinal stromal cells such as monocyte-derived 
macrophages. Thus, we are interested in knowing whether the PMA molecule, which induces the 
differentiation of THP-1 towards macrophages, can diffuse through the hydrogel.  
 
To determine the pore size of the hydrogels, we measure the permeation of dextrans with a defined 
size. Thus, fluorescently-labeled dextrans (Merck Life Science) of different molecular weights were 
used: 4 kDa, 70 kDa, 150 kDa, 500 kDa and 2000 kDa. Hydrogels were printed on silanized PET 
membranes and mounted on Transwell® inserts and kept in PBS. As controls, PET membranes 
without hydrogels were mounted on Transwells®. The following day, hydrogels were equilibrated 
at 37ºC in the incubator. Warmed dextran solutions of a concentration of 0.5 mg/mL in PBS were 
placed to the upper (donor) compartment and samples of 50 L were taken from the lower 
(acceptor) compartment at different time points during 4 h and transferred to a 96 well black plate. 
The fluorescence of the plate was measured with a Multimode Microplate Reader (Infinite M200 
PRO Multimode Microplate Reader, Tecan). Depending on the fluorescent label, FITC or 
Rhodamine B, the fluorescence was measured at the following excitation and emission 
wavelengths: 
 
a. FITC: λexc = 490 (+/- 10) nm; λem= 525 (+/- 20) nm  
b. Rhodamine B: λexc = 540 (+/- 10) nm; λem= 625 (+/- 20) nm  
 
From the intensity, the permeated amount of the different dextrans along time was determined. To 




of dextran at the different time points. Using Equation 2 we can then calculate the total mass 
transfer at each time point, a measure of the hydrogel’s permeability. 
 
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟 = 𝑉𝑠 ∗ (∑ 𝐶𝑛−1
𝑛
𝑛=1
) + 𝐶𝑛 ∗ 𝑉𝑟 Eq. 2 
 
The values of the mass transferred are then plotted as a function of time to discard those samples 
that present leakage. Namely, those whose tendency line does not go through the origin. The 
diffusion coefficient in the hydrogels of each dextran was also calculated using the equations from  
Engberg et al. [34]. (see Appendix A).  
 
4.5. Cell-laden hydrogels mimicking the intestinal mucosa  
Hydrogels encapsulating NIH-3T3 and/or THP-1 cells were bioprinted as explained above. These 
cell-encapsulating scaffolds were then assembled in Transwell® inserts and kept in culture with 
Supplemented DMEM medium containing Normocin (Invitrogen) (dilution 1:500) so that 
contamination is prevented. To mimic the intestinal epithelial barrier, Caco-2 BBe cells were seeded 
on top of the hydrogels at a density of 250.000 cells/sample either at day 1 or day 6 after hydrogel 
fabrication, and cultured for 21 days, changing the media every other day and monitoring the 
transepithelial electrical resistance (TEER) throughout the culture. 
4.5.1. Transepithelial electrical resistance (TEER) 
The transepithelial electrical resistance is a parameter essential for measuring the integrity of the 
cell monolayer. The TEER is measured through two electrodes, situated one at each side of the 
cellular barrier, that generate a voltage difference, provoking current to flow. With the current values 
and ohm’s law, the resistance of the samples can be obtained and normalized to the area of the 
monolayer.  
 
For TEER measurements the EndOhm-6G Chamber and the EVOM3 (Epithelial Voltohmeter) 
meter from World Precision Instruments were used. The EndOhm chamber is a glass cylindrical 
chamber with a circular electrode on the bottom and the opposing top electrode on the cap. To 
avoid TEER changes caused by temperature fluctuations, samples were equilibrated at room 
temperature for 15-20 minutes. Then, the Transwells® were inserted in the EndOhm chamber and 
the resistance value was obtained.  
 
The blank value, the resistance of the hydrogel without Caco-2 BBe, was subtracted from the 
acquired resistance values after seeding to get the resistance derived only from the epithelial 
monolayer (Rcell).  Then, the data was normalized to the surface of the hydrogel (Ahydrogel) following 





𝑇𝐸𝐸𝑅 = 𝑅𝐶𝑒𝑙𝑙 ∗ 𝐴𝐻𝑦𝑑𝑟𝑜𝑔𝑒𝑙 Eq. 3 
 
4.5.2. PMA-induced differentiation of THP-1 monocytes into M0 macrophages 
inside the hydrogels 
To mimic the intestinal mucosa with immunocompetent features, we encapsulated THP-1 cells 
inside the hydrogels and co-cultured with NIH-3T3 and Caco-2 BBe epithelial cells. In order to study 
whether it is possible to differentiate the encapsulated THP-1 cells into macrophages with PMA 
and the effect of this molecule on the epithelial monolayer, different conditions were tested. On day 
18 after printing, PMA at 81 nM (50 ng/mL) [22] or 200 nM [35] was added in the culture media for 
inducing cell differentiation, only in the apical compartment or in both apical and basolateral 
compartments. Samples without the addition of PMA were kept as controls. The effect of the PMA 
on the intestinal epithelial monolayer was evaluated with the TEER. Finally, the analysis of the 
macrophage cell differentiation was performed by flow cytometry explained in the following section 
(Section 4.6) .  
 
In a parallel experiment and in order to study the macrophage differentiation without the effect of 
other intestinal cells, either THP-1 or differentiated M0 cells were encapsulated alone into 
hydrogels. Then, three differentiation conditions were studied: non-differentiated THP-1 hydrogels, 
M0 hydrogels and THP-1 hydrogels treated with 200 nM PMA for 3 days. Afterwards, cells were 
recovered from the hydrogels and the degree of differentiation was analyzed by fluorescence-
activated cell sorting (FACS). 
 
4.6. Evaluation of the degree of THP-1 differentiation into M0 macrophages inside 
the hydrogels 
 
4.6.1. Hydrogel degradation with Collagenase type II  
In order to recover the encapsulated cells, the hydrogels were digested with collagenase as 
described in [35]. To optimize the conditions and assess the cell viability after the recovery, 
scaffolds encapsulating NIH-3T3 were used. To achieve this, hydrogel discs were printed 
encapsulating NIH-3T3 at a density of 7.5x106 cells/mL. The hydrogels were mounted on 
Transwell® inserts and kept in culture with supplemented DMEM medium. The hydrogels were 
digested at different time points: the same day of printing, one week after printing, and two weeks 
after printing, and viability was checked by cell counting and seeding. Once the process was 
optimized, hydrogels mimicking the intestinal mucosa were used for hydrogel digestion and further 
FACS analysis. 
 
For samples containing the epithelial cell monolayer, a previous step before the hydrogel digestion 




for 10 min at 37ºC. The cell suspension was then recovered, neutralized with supplemented media 
and saved for later to be centrifuged together with the recovered cells from the hydrogels. Hydrogel 
digestion was achieved using collagenase type II. This enzyme was diluted at a concentration of 
300 U/mL in warm filtered PBS. The hydrogels were then removed from the Transwell® inserts, 
rinsed in PBS and transferred to an Eppendorf tube with 2 mL of filtered collagenase solution. For 
FACS analysis, 3 hydrogels were pooled and digested per sample. The Eppendorfs were left in the 
incubator at 37º for 45 minutes, or until the hydrogels were completely dissolved, mixing vigorously 
with the pipette every 10 min. Then, the PET membranes were removed, and samples were 
centrifuged at 300xg for 5 min. The cell pellet was resuspended in 100 L of supplemented DMEM 
medium for cell viability studies, or FACS buffer for immunophenotyping analysis as explained in 
the following section.  
 
4.6.2. Flow cytometry direct immunophenotyping   
To assess the differentiation state of the immune cells, a direct immunophenotyping and flow 
cytometry analysis was performed. We used CD11b Antibody (Thermo Fisher) as membrane 
marker specific for the differentiated THP-1 (M0), the CD31 (PECAM-1) monoclonal antibody 
(Thermo Fisher) as extracellular marker specific for both differentiated and non-differentiated 
monocyte, and DAPI for cell viability. An isotype control is required to determine the non-specific 
binding of the marker. After hydrogel digestion and cell recovery, the pellet was resuspended in 
100 L of ice-cold FACS Buffer; 10% (v/v) FBS and 1% (w/v) sodium azide (Sigma Aldrich) in PBS.  
Then 5 L of the desired antibodies was added, and the samples were incubated at 4ºC in the dark 
for 30 mins. Cells were then centrifuged and washed twice with 500 L FACS buffer. Finally, the 
samples were resuspended in 250 L of FACS buffer and filtered with 70 m cell strainer before 
being analyzed with the flow cytometer (Gallios Research Flow cytometry, Beckman Coulter).   
 
4.7. Gut-on-a-chip assembly  
After cell-laden hydrogel characterization, scaffolds with the 3D villi channel structure encapsulating 
THP-1 and NIH-3T3 were printed onto a coverglass and assembled into a PDMS microfluidic chip. 
The chip is formed by two patterned sheets of PDMS, cured into a 3D printed mold. The bottom 
PDMS layer contains a small cavity in which the coverglass perfectly fits. The top PDMS layer 
contains the cavity in which the hydrogel is embedded and the channel features. Two different chip 
designs were used: single-channel (Figure 8 (a)) and two-channel chip (Figure 8 (b)). To seal the 
chip and prevent leakage between the PDMS layer, a chip holder was designed, consisting of a 3D 
printed case with screws (Figure 8 (c)). In Figure 8 (d) a schematic of the PDMS microfluidic chips 
with the custom-made chip holder is shown. Once the whole gut-on-a-chip was assembled, it was 
perfused with supplemented DMEM medium at a constant flow rate of 2.5 l/min using a syringe 
pump (NE-1000 Programmable Single Syringe Pump, New Era) and left in the incubator at 37ºC 






Figure 8. Microfluidic chip and custom-made chip holder. (a) Single-channel chip illustration. (b) Two-channel chip illustration. (c) 
Single-channel chip and holder system with perfused medium. (d) Chip and holder assembly schematics. (e) Chip perfusion set up. 
4.7.1. Cell viability assay  
The viability of the encapsulated cells inside the hydrogels on the chip was assessed using the 
Live/DeadTM viability/cytotoxicity assay kit (Invitrogen). After 5 or 7 days, the chips were 
disassembled and hydrogels were washed three times with warm PBS and incubated for 20 min 
with 4M ethidium homodimer-1 (EthD-1), 2M calcein AM and Hoechst (dilution 1:1000) in PBS 
at 37 ºC. Afterward, the samples were washed and analyzed with the confocal microscope (LSM 
800, Zeiss). EthD-1 will only stain the nuclei of dead cells in red, whereas the non-fluorescent 
calcein AM will be converted into fluorescent calcein only by living cells. Then, cell viability 
quantification was performed manually stack by stack.  
5. Detail engineering  
5.1.  Determination of the degree of functionalization of GelMA 
Through the methacrylation process, gelatin becomes a photocrosslinkable and thermostable 
polymer, which can be used in photopolymerization printing of hydrogels. The degree of 
methacrylation determines the mechanical properties of the GelMA as well.  Thus, by varying the 
ratios of gelatin to MA in GelMA synthesis the stiffness of the scaffold can be tuned. Studies suggest 
that the appropriate degree of methacrylation ranges between 30% and 60% [36]. Lower values 
lead to low crosslinking and hydrogels with no structural integrity, whereas high values result in 
hard scaffolds that reduce cellular spreading and proliferation  [37].  
 
We performed the TNBSA assay to determine the extent of substitution of free amine groups in 
newly methacrylized GelMA (B6), which is expected to be around 40% for a MA concentration of 
1.25% (v/v) and compare it with the previous GelMA batch (B5). The batch B5 and new batch B6 




bit lower than expected, yet they were still in the suitable range for hydrogel fabrication and 
subsequent cell adhesion.  
 
5.2.  Characterization of hydrogel network  
Hydrogels are crosslinked polymeric networks and thus present a pore architecture. The mesh size 
determines cell attachment, survival, migration, and proliferation, as well as ECM secretion [38]. 
Research shows that small pore size increases initial cell attachment, but that larger pore improves 
infiltration and so long-term viability [33]. Besides, porosity is correlated to swelling, stiffness and 
molecular diffusion of nutrients to and metabolites out of the scaffold. In our work, the determination 
of the hydrogel pore size is crucial to know if the PMA molecule would diffuse through the hydrogel.  
The PMA molecule activates THP-1 cells which differentiate into macrophages. These phagocytic 
cells play a major role in maintaining intestinal homeostasis. Although differentiated macrophages 
can be directly embedded in the hydrogel [22], encapsulation of the monocytes is preferred, as the 
fabrication process may affect cell phenotype. To differentiate them inside the scaffolds, the PMA 
molecule should diffuse through the hydrogel.   
 
The hydrogel pore size can be estimated using the diffusion of dextrans of different molecular 
weight (Figure 9).  
 
Figure 9. Amount of permeated dextran through the hydrogel on top of a PET membrane, and the PET membrane alone, as a 
function of time. (a) 4 kDa dextran with a 1.4 nm radius. (b)  70 kDa dextran with a 5.8 nm radius. (c) 150 kDa dextran with an 8.5nm 





The FD4 dextran, which has a radius of 1.4 nm, passed freely through the hydrogel. The FD70 and 
FD150 were also able to permeate, although the hydrogel hampered their movement. Finally, the 
permeated amount of FD500 and FD2000 was below the limit of detection, meaning that they were 
not able to diffuse through the hydrogels. Considering the results, we can estimate that the average 
pore size is between the radius of the 150 kDa and 500 kDa dextran, meaning between 8.5 nm and 
16 nm and larger molecules will be not able to permeate through the mesh. Having a molecular 
weight of 616.8 Da and a radius of 1.1 nm, the PMA molecule will easily diffuse through the hydrogel 
reaching the encapsulated THP-1 cells. Other small molecules important to ensure cell viability, 
such as oxygen and glucose, are also able to diffuse.  
 
5.3. Characterization of cell-laden hydrogels mimicking the intestinal mucosa  
The 3D model of the intestinal mucosa was bioprinted using the G8 bioink. The model contained 
encapsulated NIH-3T3 fibroblasts and THP-1 cells as stromal compartment and Caco-2 BBe 
enterocytes forming the epithelial barrier. In order to better characterize the cell behavior, hydrogels 
were first studied in static conditions assembled into Transwells® (Figure 10 (a)). Thus, standard 
cell culture assays such as the evaluation of the epithelial monolayer’s integrity through TEER 
measurements can be performed.  
In previous works using a similar intestinal mucosa model, epithelial cells were seeded on top of 
the hydrogel one day after fabrication [21]. However, it was observed that during the first week after 
seeding, the epithelial barrier was not yet formed, and the TEER values did not increase. This lag 
phase was probably due to the lack of secreted ECM from the stromal compartment. Thus, we first 
studied the epithelial monolayer formation on top of cell-laden hydrogels seeded 1 or 6 days after 
hydrogel fabrication.  The TEER was monitored throughout the culture (Figure 10 (b)). From the 
beginning of the culture, samples seeded one week after fabrication showed TEER values higher 
than the samples following the standard procedure (seeded 1 day after fabrication), reaching the 
TEER plateau after 2 weeks of culture instead of the 3 weeks needed for the cells seeded at day 
1.
 
Figure 10. (a) 3D model of the intestinal mucosa in Transwell® inserts, composed of hydrogel with embedded NIH-3T3 and THP-1 
and a monolayer of Caco-2BBe. (b) TEER values for different seeding times, 1 day after printing and 6 days after printing, as a 




With these results, we can conclude that the interaction and cross-talk between epithelial and 
stromal cells enhance the growth and formation of the epithelial barrier. Fibroblasts need time to 
adhere to the hydrogel and secrete ECM. If we allow the cells to migrate and proliferate before 
seeding, we can reduce the amount of time that enterocyte cells require to establish tight junctions 
and form a selective permeable epithelial barrier.   
 
5.4. PMA induced differentiation of THP-1 monocytes into M0 macrophages inside 
the hydrogels 
Intestinal macrophages are mononuclear phagocytes primarily found in the lamina propria, 
responsible for maintaining mucosal homeostasis and intestinal barrier integrity. Overall, they are 
accountable for the intestinal immune response [39]. Thus, if incorporating these cells into our 
bioprinted intestinal mucosa we would obtain a model with increased functionality and immune-
competent features. Macrophages can be incorporated into the hydrogel already differentiated [22] 
or as monocytes that can be later differentiated into macrophage-like cells [35]. To do this, we first 
need to evaluate the differentiation of monocytes inside the hydrogel, without disrupting the 
epithelial monolayer.  
 
5.4.1. Effect of PMA on epithelial monolayer integrity.  
Co-cultured hydrogels were exposed to different concentrations of PMA (81 and 200 nM) and the 
effect on the epithelial integrity was monitored. Moreover, it was analyzed whether the 
differentiation molecule triggered the same cell response when being administered only in the 
basolateral side, or in the basolateral and apical sides of the barrier.  
 
Figure 11 shows that in both concentrations, PMA-free samples present lower TEER values than 
those supplemented with the differentiation molecule. However, this is not correlated with the 
presence of the molecule. In order to ensure the exposure to PMA in a compartmentalized manner 
(only basolateral or both apical and basolateral), the PMA was added on the third last day of culture 
to samples that did not present leakage so they already had higher TEER values. During the 
incubation with PMA, the epithelial integrity was not affected since the TEER values did not 
decrease in any condition. Moreover, no significant difference between PMA applied in the 
basolateral side or the basolateral and apical sides was observed. These results are also supported 
by Gjorevski et al. who also observed that Caco-2 cells lining a PMA-containing collagen matrix 







Figure 11. TEER values for samples without PMA, with PMA in the basolateral side, and PMA in the basolateral and apical side at 
a concentration of 200 nM (a) and 81 nM (b). The values shown are the Mean ± SEM, n=3. 
The cell morphology was also evaluated by optical microscopy (Figure 12). The Caco-2 BBe 
seeded on the surface of the hydrogel formed a confluent and tight monolayer and presented a 
cobblestone-like morphology for all the conditions (Figure 12 (a, d, g)).  As to the cells embedded 
inside the hydrogel, spherical and elongated NIH-3T3 (Figure 12 (f)) were observed, as well as 
spherical THP-1 (Figure 12 (b, i)). Interestingly, large globular cells were distinguished in the 
stromal compartment (Figure 12 (c, e, h)), especially on the PMA treated samples.  
 
Figure 12. Microscope images of the epithelial monolayer and the stromal compartment, with encapsulated fibroblasts and 
monocytes (a-c). Samples were exposed to PMA on the basolateral side (d-f), or in the basolateral and apical sides of the barrier 
(g-i). The epithelial monolayer formed by Caco-2 BBe cells on the surface of the hydrogels can be clearly distinguished (a,d,g). The 
THP-1 embedded in the hydrogel presented round, single-cell morphology (b, i) whereas encapsulated NIH-3T3 were elongated (f). 




Considering the results, we reaffirm the abovementioned conclusion. Epithelial cells can adhere to 
the hydrogel and proliferate in the presence of PMA forming a uniform monolayer, and stromal 
fibroblasts could also spread inside the hydrogel. In the case of the monocytes, the large spherical 
cells presenting a morphology similar to the macrophages lead us to believe that PMA could induce 
the differentiation of encapsulated THP-1. To verify this assumption a flow cytometry assay was 
carried out.  
 
5.4.2. Hydrogel degradation with Collagenase type II  
Once demonstrated that the PMA did not affect the epithelial monolayer, the differentiation degree 
of the THP-1 cells inside the hydrogels was evaluated by FACS. First, we needed to develop a 
protocol to degrade the hydrogel and recover the encapsulated cells without affecting their viability. 
Hydrogels encapsulating NIH-3T3 at different culture time points were used to optimize the 
procedure. The hydrogel was digested with collagenase type II and fibroblast retrieval was 
successfully achieved. The scaffolds were completely digested after 45 min incubated in 300 U/mL 
filtered collagenase solution. All the hydrogels digested 4 hours, 7 days or 14 days after fabrication 
were digested at the same rate. 
 
From a single hydrogel, 45% of the total encapsulated cells were recovered after one week of 
incubation, whereas this percentage increased to 61% after two weeks. The enzymatic digestion 
did not seem to affect the cell viability as retrieved fibroblasts adhered to the cell culture dish after 
15 min of seeding (Figure 13). 
 
 
Figure 13. NIH-3T3 recovered from a hydrogel digested 4 hours after printing. Scale bar: 200 μm. 
5.4.3. Flow cytometry direct immunophenotyping  
The differentiation degree of the encapsulated THP-1 cells was assessed by direct 
immunophenotyping analysis and flow cytometry. CD31 antibody was used to demonstrate the 
presence of differentiated and non-differentiated THP-1 cells, CD11b antibody to detect  
differentiated THP-1 (M0) and DAPI for cell viability. To check the specificity of the CD31 and 
CD11b antibodies, the cell types present in our intestinal mucosal model (Caco-2 BBe, NIH-3T3 
and THP-1, differentiated and non-differentiated) were cultivated in standard flasks and trypsinized 




by FACS was performed (Figure 14). Isotype controls give the non-specific background signal and 
determine the fluorescence intensity threshold above which cells are considered positive, so-called 
gate. As expected, the non-differentiated THP-1 were only positive for CD31, whereas M0 were 
positive for CD31 and CD11b. Samples with only Caco-2 BBe and NIH-3T3 were negative for both 
markers (see Appendix B).  
 
Figure 14. Flow cytometry direct immunophenotyping histograms and dot plots (CD11b vs CD31) of 2D cultures with CD31 and 
CD11b markers. (a) THP-1 monoculture isotype control. (b) THP-1 monoculture. (c) M0 monoculture isotype control. (d) M0 
monoculture. 
Then we evaluated if we were able to induce the differentiation of the THP-1 once encapsulated 
inside the hydrogels. Thus, THP-1 laden hydrogels were printed and exposed to 200 nM PMA for 




encapsulated. Rounded cells were observed in the scaffolds with THP-1 with or without PMA after 
2 days of printing, without any noticeable difference between these two conditions (Figure 14 (a, 
b)). The monocyte-derived macrophages M0 appeared in form of big aggregates (Figure 15 (c)) 
due to a problem during the hydrogel fabrication. When the bioink was prepared with the cell 
suspension, the cell pellet was not properly resuspended and clumps of cells were encapsulated 
inside the hydrogel, instead of a single-cell suspension. 
 
Figure 15. Optical microscope images of cell-laden hydrogels with THP-1 (a), THP-1 exposed to PMA (b) and M0 (c). Scale bar: 
100 μm. 
After 72 h of PMA treatment, hydrogels were digested, and cells were recovered. The direct 
immunophenotyping showed that 90% of embedded M0 cells were positive for CD31 and CD11b, 
meaning that after printing most of the macrophages did not return to the monocytic state (Figure 
15). Interestingly, the THP-1 cells had an unexpected behavior. The THP-1 cultivated in 2D were 
12.5% positive for CD11b. When these THP-1 cells were encapsulated inside the hydrogels for 3 
days, 64% of the cells spontaneously differentiated into CD11b-positive cells. Thereby, it can be 
deduced that a 3D microenvironment affects cell behavior and promotes cell differentiation. When 
encapsulated THP-1 were exposed to PMA, this percentage increased to 88%. Thus, PMA can 






Figure 16. Flow cytometry direct immunophenotyping. (a) Amount of positive cells for markers CD31 and CD11b in 2D and 3D, 
THP-1 and M0 monocultures. (b) Dot plot (CD31 vs CD11b) of THP-1 encapsulating hydrogels. (c) Dot plot (CD31 vs CD11b) of 
THP-1 encapsulating hydrogels exposed to PMA. (d) Dot plot (CD31 vs CD11b) of M0 encapsulating hydrogels.  
Spontaneous polarization of THP-1 encapsulated in GelMA or PEGDA hydrogels was already 
reported by Cha et al [41].  Monocytes within GelMA scaffolds enlarged and expressed an anti-
inflammatory M2-like phenotype whereas when encapsulated in PEGDA hydrogels they 
differentiated into proinflammatory M1 macrophages. Considering that the main difference of 
GelMA scaffolds compared to PEGDA is the presence of adhesive motifs, the authors concluded 
that integrin interactions control the immune response of the monocytes. Similar cell enlargement 
and differentiation were observed in our monoculture GelMA-PEGDA co-networks, inferring that 
the architectural environment and material have a critical impact on the behavior of monocytes.    
Finally, the behavior of the immune cells was studied in the complete intestinal model, where THP-
1 were co-cultured with the NIH-3T3 and Caco-2 BBe cells for 21 days. At day 18, some of the 
samples were treated with PMA (81 or 200 nM) administered only in the basolateral side or in both 
apical and basolateral compartments. The differentiation of the THP-1 was studied by FACS 
(Figure 17). Due to some experimental issues, only the CD11b marker could be used. Without PMA 
treatment, only 5% of total cells were positive for CD11b. The scaffolds did not only contain THP-






Figure 17. Amount of cells positive for maker CD31 in cell-laden hydrogels cultured in different conditions: without PMA, with PMA 
on the basolateral side and with PMA on the basolateral and apical side. PMA was administered at a concentration of 81nM or 
200nM. 
When the THP-1 were exposed to the low PMA concentration, we did not observe an increase in 
the differentiation rate. However, when cells were incubated with a higher PMA concentration, both 
apical and basolateral, around 15% of total cells were positive for CD11b. If the proportion of the 
initial cells was maintained throughout the 3 weeks of culture, this result would mean that almost 
all the encapsulated cells were differentiated. However, this experiment should be repeated with 
the CD31 marker to identify the total number of immune cells present in the cell suspension.  
5.5. Gut-on-a-chip assembly  
Once the cell-laden hydrogels were characterized the gut-on-a-chip model was assembled. 
Hydrogels encapsulating NIH-3T3 and THP-1 cells were printed with a villi-like architecture, as 
seen in Figure 18.  
First, two cell-laden 3D constructs were incorporated into two single-channel microfluidic chips. 
After 5 days of perfusion with medium, we did not observe cell migration towards the channels and 
the cells remained rounded. Some air bubbles appeared as well on the channels of both chips but 
did not disrupt the hydrogels. Although one of the chips presented leakage and was contaminated 
with yeast, the other one was used for a Live/DeadTM assay after one week of perfusion. 
Subsequently, two two-channel microfluidic chips were assembled with cell-encapsulated 3D 
scaffolds. These chips presented almost no leakage after 5 days of perfusion, however, there was 
no migration towards the channels. A Live/DeadTM assay was carried out of the two hydrogels after 





Figure 18. NIH-3T3 and THP-1 encapsulating hydrogels with micropillar structures. (a) Cell-laden hydrogel in a single-channel 
microfluidic chip, 72 hours after fabrication. (b) Cell-laden hydrogel in a two-channel microfluidic chip, 2 hours after fabrication. Scale 
bar: 200m.  
To evaluate the cell viability, a Live/DeadTM assay was carried out and the percentage of living cells 
was calculated in the center and the channel-facing side with the 3D villi structure (Figure 19 (a)).  
The 3D projections and reconstructions of the confocal images taken from the channel-facing side 
of the hydrogels are seen in Figure 19 (b,c). All the nuclei are stained with Hoechst reagent, and 
blue-colored, living cells are depicted in green and dead cells in red. For quantification, cells that 
presented double staining were considered dead.   
 
Figure 19. Live/Dead viability/cytotoxicity assay in THP-1 and NIH-3T3 encapsulating hydrogels. The hydrogels were incorporated 
into single-channel and two-channel microfluidic chip and perfused for 7 and 5 days, respectively. (a) The number of living cells was 
counted in the area next to the channel and the center of the hydrogel. The values shown are the Mean ± SD, n=2. A minimum of 
60 cells were counted from each sample. Maximum intensity projection and 3D reconstruction of confocal images from hydrogels 
inside single-channel (b) and two-channel (c) chip are also shown.  Living cells are stained in green and dead cells in red. Hoechst 




For both chips, single-channel and two-channels, the cell viability is very low, between 20% and 
30%, being slightly higher for the hydrogel in the two-channel chip. Since cell viability in the 
hydrogels was already confirmed in the flow cytometry tests and other previous studies [21], the 
PDMS microfluidic system is considered to be responsible for cell toxicity.  
One possible explanation may relate to the physical constraints to which the cells are subjected. 
The holder generates pressure to ensure appropriate sealing and coupling of the two PDMS sheets. 
Since the hydrogel is in between these two layers, an undesired pressure may be exerted on the 
scaffold leading to cell death. Studies suggest using PCR adhesive tape for strong bonding 
between PDMS layers, a simple and low-cost alternative [42].  
Another hypothesis would be that the supplemented medium going through the channel cannot 
reach all the embedded cells. Nevertheless, if this was the cause of cell death, we would expect 
that the cells near the channels in contact with the medium would have higher viability, but that was 
not the case. The last possible explanation may be the release of toxic compounds by the PDMS 
sheets, cured in 3D printed resin molds. The resin, a synthetic organic compound, can still elude 
soluble substances after polymerization and ultimately alter the PDMS biocompatibility [43].   
Almeida Monteuro Melo Ferraz et al. demonstrated that solutions incubated in PDMS fabricated 
using SLA 3D printed resin molds presented leachates [44]. They confirmed that after conditioning 
the PDMS chip overnight with a medium, removing the eluded substances, the chip could support 
cell growth. In our work, the molds were only silanized before PDMS curing.  Additional steps, such 
as isopropanol washing reported by previous studies [45], could be implemented in future 
experiments for PDMS fabrication.  
Nonetheless, additional experiments should be carried out to determine if the PDMS fabrication 











6. Execution schedule 
6.1. Work Breakdown Structure 
The Work Breakdown Structure of the project is depicted in Figure 20.  
 
Figure 20. Work Breakdown Structure of the project. 
6.2. Task definition 
1. Practical training: A training was required before starting the project to use the IBEC facilities 
and to learn all the basic laboratory tasks - cell passaging and culture maintenance, viability 
tests, immunofluorescence assays, to name a few.    
2. Bibliographic review: To gain insight into biomimetics systems and cell-laden scaffolds, the 
current state and advancements in the field were reviewed. However, a literature search was 
carried out throughout the whole project to find new ways of characterizing the cell-laden 
hydrogels.   
3. Hydrogel bioprinting and characterization: The first step in developing the OoC was to prepare 
the bioink for hydrogel 3D printing. Thus, gelatin must be methacrylized, after which, the bioink 
with GelMA, PEGDA, LAP and tartrazine solution is prepared, and the hydrogel is bioprinted. 
Ten, mesh size of the hydrogel is determined. For each experiment, the bioink was freshly 
prepared.  
4. Cell-laden hydrogel characterization: After hydrogel characterization, cell-laden hydrogels 
were printed. On the one hand, studies of printed hydrogels encapsulating fibroblast and 
monocytes, together with epithelial cells on the surface were carried out. On the other hand, 
monocyte behavior inside hydrogels was also assessed.  
5. Gut-on-a-chip assembly: Once the components of the OoC were studied and fabricated, the 
whole gut-on-a-chip, with cell-laden hydrogel, microfluidic chip, holder and hydrogel scaffolds 




6. Project analysis: After each experiment, the data was processed and analyzed. Yet, a general 
overview of the outcomes was done after completing all the experiments and before starting 
the final report.  
7. Final Report: This is the final step of the project that consisted of gathering all the information 
regarding OoC, the experiments, and the results.   
8. Project presentation: After report delivery, the project will be presented and discussed in front 
of a jury.  
6.3. PERT-CPM 
In Table 1 the tasks involved in the project, order of execution, and duration are shown.  
Task Activity Previous activities Next activities Duration (Weeks) 
A Practical training   -  C, D, E 9 
B Bibliographic review - D, G 30 
C 
Hydrogel bioprinting and 
characterization  




B, C E 10 
E Gut-on-a-chip assembly C, D F 3 
F Project analysis E G 2 
G Final report B,F H 5 
H Project presentation  G - 1 
Table 1. Project task sequence and duration (in weeks). 
From the task planning the PERT-CPM charts were created (Figure 21).  
 




6.4. GANTT Chart 
The detailed timeline of the tasks was represented with a GANTT chart (Figure 22).   
  
Figure 22. Detailed GANTT Chart of the activities carried throughout the project. 
7. Technical feasibility 













ACTIVITY START DATE DUE DATE
IBEC Facilities Tour 06/07/2020 12/07/2020
Safety and Health Course 09/09/2020 09/09/2020
Practical training 06/07/2020 30/09/2020
Bibliographic review 06/07/2020 14/06/2020
GelMA fabrication and 
characterization
03/02/2021 10/02/2021
Hydrogel fabrication 10/02/2021 15/05/2021
Porosity characterization 11/02/2021 22/02/2021
Study of co-culture hydrogel 08/03/2021 05/04/2021
Study of THP-1 differentiation when 
embedded on hydrogels
01/04/2021 30/04/2021
Co-culture hydrogel on microfluidic 
chip with a single channel
07/05/2021 14/05/2021
Co-culture hydrogel on microfluidic 
chip with two channels
12/05/2021 19/05/2021
Project analysis 01/05/2021 15/05/2021
Final report   10/05/2021 14/06/2021
Presentation preparation 14/06/2021 22/06/2021
   Bioink fabrication and characterization
Training process and project preparation
Cell-laden hydrogel characterization
Gut-on-a-chip assembly
Final Report and project presentation




11 12 13 14
June 2021Summer  2020
Jul-Aug-Sept 17 18 19 20 211 2 3 4 5 15





- Mimics the in-vivo 3D architecture. 
- Co-cultured hydrogels that support 
cell-cell interaction. 
- Device with immunocompetent 
features for inflammatory analysis. 
- Use of simple and reproducible 
bioprinting and microfluidics 
technology. 
- High-resolution and control of the 
microenvironment architecture. 
- Real-time and on-chip analysis. 
- Low cell viability in hydrogels inside 
the microfluidic chip. 
- Leakage and air bubble formation 
inside the microfluidic chip. 
- Require controlled temperature and 
humidity conditions for bioprinting. 
- Lack of peristaltic motion. 
 
Opportunities Threats 
- Increase demand of OoC. 
- Increase areas of application. 
- Automated bioprinting of cell-laden 
hydrogels. 
- Integration of sensors. 
- No current legislation or validation 
method. 
- End-users, specifically the 
pharmaceutical industry, are in a 
highly regulated environment to 
predict drug responses and 
toxicological outcomes. 
Table 2. SWOT analysis of the project. 
8. Economic viability  
The materials and equipment used in the project were provided by the Biomimetic System for Cell 
Engineering research group and by the IBEC Core facilities. These last ones had an additional cost 
specified in Table 3.   
Equipment Hours Price rate  (€/h) 
Oven 6 4.44 
ProCleaner™ 3 2 
3D Printer Solus CleanRoom 25 16.52 
Confocal Microscopy 12 28 
M200 PRO Multimode Microplate 
Reader 
4 20 
Gallios Research Flow cytometer 10 28 





The reagents, materials and software used with their correspondent cost are shown in Table 4.  
Resource Units  Cost (€) 
Reagents 
Dulbecco's Modified Eagle Medium 
(DMEM) 
500 mL 25.8 
Roswell Park Memorial Institute (RPMI)-
1640 medium 
500 mL 31.44 
Fetal Bovine Serum (FBS) 125 mL 175 
Trypsin-EDTA 60 mL 10.5 
Penicillin/Streptomycin (Pen/Strep) 20 mL 10.5 
Sodium pyruvate  5 mL 0.1 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
5 mL 7.2 
β-mercaptoethanol 500 L 0.5 
Phorbol 12-myristate 13-acetate (PMA) 100 ng 1 
Accutase® 10 mL 5.5 
Phosphate Buffered Saline Solution 1 L 90.5 
Gelatin porcine skin type A 10 g 2.75 
Methacrytic anhydride 5 mL 0.72 
2,4,6 – Trinitrobenzene sulfonic acid 
(TNSBA) 
20 L 0.5 
Sodium dodecyl sulfate (SDS) 5 mL 0.1 
Sodium bicarbonate solution (NaHCO3) 1 mL 0.1 
Hydrochloric acid (HCl) 500 L 1.5 
Lithium arylphosphanate 40 mg 4 
Poly(ethylene glycol) diacrylate 300 mg 64.5 
Tartrazine 2.5 mg 1 
Hank’s Balanced Salt Solution (HBSS)  10 mL 0.5 
3-(Trimethoxysilyl) propyl methacrylate 0.2 mL 0.1 
Acetic acid 0.3 mL 4 
FITC-dextrans  8.8 mg 11.2 
70 kDa Rhodamine-dextran (FD70) 2.2 mg 30.8 
Normocin 600 L 7.6 
Collagenase type II 5 mg 2 
Sodium azide 250 mg 0.1 
CD31 Antibody and Isotype 75 L 57.3 




Live/DeadTM viability/cytotoxicity assay 
kit 
9 L 150 
Hoechst 6 L 0.1 
Polydimethylsiloxane (PDMS) pre-
polymer elastomer and curing agent 
1 kg 173 
Materials 
Dialysis membranes 20  30.8 
Labware  N/A 600 
Labcoat 1 25 
Laboratory notebook 1 15 
Softwares 
FreeCAD N/A 0 
Fiji-ImageJ N/A 0 
Microsoft 365 N/A 0 
Graphic Tools N/A 0 
 Total cost 1651.31 
Table 4. Reagents, materials, and software used throughout the project. 
Considering the price of the equipment, the reagents and products used, and the supervision and 
tutoring from an experienced researcher (25€/h) the total project expenditure was of around 5000€.  
9. Regulation and legal aspects.  
Given the infancy of this technology, no specific regulations or standards have been defined. 
Consequently, a regulatory framework and body that facilitate the validation process of organ-on-
a-chip models for its future application are needed. With this objective in mind, the EU initiated the 
ORCHID project in 2017. The project, coordinated by Leiden University Medical Center and the 
Dutch Organ-on-Chip consortium hDMT, had the goal of assessing the current technology status, 
presenting guidance for regulation and standardization, identifying a roadmap for technology 
adoption, and raising awareness. After the project’s termination in 2019, the European Organ-on-
Chip Society (EUROoCS) was born.  This consortium has taken the lead in building a network that 
includes regulatory bodies, end-users and developers, supporting OoC development and creating 
a roadmap and guidelines for OoC implementation. The defined roadmap consists of six steps: 
application, specification, qualification, standardization, production and upscaling, and adoption 
[46].  
 
In this context, the JRC’s European Union Reference Laboratory for alternatives to animal testing 
(EURL ECVAM) also plays a key role. Their goal is to ensure the EU member states' compliance 
with the 3R’s principle (replacement, reduction and refinement) defined in the Directive 2010/63/EU 




responsible for validating the alternatives, in which the OoC would be included, with the help of an 
independent Scientific Advisory Committee (ESAC). Moreover, they are currently collaborating with 
the EUROoCS in the implementation of quality control assays carried out by testing centres to 
evaluate the performance of the in vitro models [47].  
 
Despite the lack of availability of specific regulations, some existing international quality standards 
can be applied to OoCs. For instance, the Medical Devices-Quality Management System (ISO 
13485:2016) sets the requirements to ensure the robustness, reproducibility, and reliability of the 
models.    
 
Finally, as we are working with biological agents we should adhere to the following guidelines: 
Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the 
protection of workers from risks related to exposure to biological agents at work. 
 
10. Conclusion and future directions.   
OoC is an emerging technology that has caught the attention of the pharmaceutical industry, and 
potentially the healthcare sector for personalized medicine. In only ten years’ time new companies 
and research groups have been able to find new efficient, effective, and cost-saving methods for 
in vitro drug screening and human physiology studies. However, currently available OoCs lack 
complex tissue features limiting the translational capabilities of the devices to clinical outcomes. 
This aspect is crucial in organs such as the gut, which have a very characteristic architecture that 
must be emulated in order to get a reliable model. For fabricating these ECM-like constructs, 3D 
bioprinting techniques are being explored due to its simplicity, reproducibility and precision.  
Therefore, in the present project, we attempted to develop a gut-on-a-chip device that mimicked 
the small intestinal mucosa combining SLA 3D bioprinting with microfluidic technology. We aimed 
to fabricate a 3D bioprinted cell-encapsulating hydrogel with villus-crypt architecture that supported 
epithelial monolayer formation on top, which would be later incorporated into a PDMS microfluidic 
chip. The 3D constructs are fabricated with the object of replicating the two layers in the intestinal 
mucosa; the lamina propria and the intestinal barrier.   
The stromal compartment was successfully reproduced by GelMA-PEGDA bioprinted hydrogels 
with embedded fibroblasts and monocytes. The scaffolds were printed with the SLA technique and 
provided a suitable environment for NIH-3T3 and THP-1 adhesion and proliferation, as well as 
subsequent epithelial monolayer formation. This last process was proved to be accelerated by the 
secretion of ECM by encapsulated NIH-3T3.  
Furthermore, the incorporation of immune cells into the model was of great interest due to the key 




1 differentiation into macrophages was accomplished with the diffusion of PMA through the pores 
of the hydrogels. Interestingly, it was observed that the 3D microenvironment alone induced the 
spontaneous differentiation of monocytes into the phagocytic cells. 
The ability of PMA induced differentiation in complete 3D intestinal models, this is, NIH-3T3 and 
THP-1 encapsulating hydrogels with Caco-2 BBe seeded on top, was also analyzed. It was 
demonstrated that PMA did not affect the barrier integrity. Even though some cells presented 
macrophage-like morphology in the PMA exposed models, further experiments are needed to verify 
and quantify monocyte differentiation.  
Lastly, SLA bioprinting allowed for the fabrication of rectangular cell-laden hydrogels with crypt-
villus architecture on one side. However, the incorporation of this hydrogel inside the microfluidic 
system resulted in cell death. The cause is yet to be determined, although possible explanations 
are excess compression or the release of leachates by the cured PDMS in 3D printed resin molds.  
Thus, future experiments need to focus on and the improvement of the PDMS chip and holder 
system to ensure cell viability. Once this is guaranteed, the next step would be to seed the side-
channel facing surface of the hydrogel with Caco-2 BBe to model the epithelial barrier, by perfusion 
of epithelial cell suspension through the channel. 
Hereafter, the complexity and functionality of the biomimetic systems can be increased with the 
incorporation of biomechanical or chemical cues as well as the integration of biosensors for in situ 
monitoring of functional parameters. With regards to the fabrication process, given the importance 
of rapid and precise fabrication in the OoC market, the current bioprinting setup should be optimized 
and automated, as the current configuration is optimized for single scaffold bioprinting. Lastly, the 
robustness and predictiveness of the model should be assessed, to guarantee stable experimental 
conditions when used in drug screening and toxicity tests.  
While there is still a lot of room for improvement, this biomimetic gut-on-a-chip device might 
potentially be used to study intestinal physiology and disease mechanisms, as it replicates many 
of the relevant features of the native human gut.  
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Appendix A   
The diffusion coefficient of each dextran in the hydrogels was also calculated through the formulas 
extracted from Engberg et al.  
 















𝑉 = 𝑉𝑑 + 𝐴ℎ + 𝑉𝑟 
 
 














Where h is the thickness of the hydrogel and N the initial mass of the solute. Finally, the diffusion 
coefficient of the dextrans in the hydrogels can be compared to the diffusion in water, calculated 







Considering that the hydrogels were printed on top of PET membranes the diffusion coefficient of 
the dextrans through the membranes was also assessed. The diffusion coefficient of the hydrogels 
was then calculated, considering a dual membrane (hydrogel and PET membrane) configuration. 
To do so, the equations extracted from C.J Lee et al.[48] were used:  
 














    Eq. 8 
  
 








𝐴 ∗ (ℎ𝑃𝐸𝑇 + ℎ𝑔𝑒𝑙)
2  )  ∗ ( 𝑉𝑟 +






   Eq. 10 
The diffusion coefficient for dextrans of 4kDa, 70 kDa, 150 kD, 500 kDa and 2000 kDa in the 
hydrogels, subtracting the effect of the membrane, are shown in Figure 23 (a). The ratio of diffusion 






Figure 23. Hydrogel pore size characterizatio.  (a) Diffusion coefficient in the hydrogel of the dextrans with a molecular weight of 
4kDa, 70kDa, 150kDa, 500kDa and 2000kDa. The values shown are mean ± SD, n>2. (b) Ratio between the diffusion coefficient in 
the hydrogel and water of the different dextrans. The values shown are mean, n>2.  
Appendix B   
A direct immunophenotyping analysis and flow cytometry assay with marker CD11b (Figure 24) 
and CD31 (Figure 25) in cultures of Caco-2 BBe and NIH-3T3 was also carried out to verify the 
specificity of these markers for THP-1 and M0.  Isotype and autofluorescence controls were 
included to determine the non-specific background signal. Assays with the CD11b marker were 
analyzed with the FACSAriaTM III Cell sorter (BD, Biosciences), whereas those with CD31 marker 
were analyzed with Gallios Research Flow cytometry (Beckman Coulter).  
 
 
Figure 24. Direct immunophenotyping assay and analysis by FACS with marker CD11b of Caco-2 BBe (a) and NIH-3T3 (b) 2D 






Figure 25. Direct immunophenotyping assay and analysis by FACS with marker CD31 of Caco-2 BBe (a) and NIH-3T3 (b) 2D 
cultures, including isotype controls.  
 
 
 
 
 
